To examine the extent of compliance to the proposed monitoring protocol among practicing psychiatrists for second generation antipsychotics

Journal of the Pakistan Medical Association

Volumn 60, Issue 6, 2010, Pages 446-450

  Khan, Ahsan Yaqoob ^a   Shaikh, Mohammad Rafique ^a   Ablah, Elizabeth ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL PROTOCOL; DEMOGRAPHY; DRUG MONITORING; HOSPITAL PATIENT; HUMAN; MEDICAL PRACTICE; OUTPATIENT; PATIENT COMPLIANCE; PSYCHIATRIST; QUESTIONNAIRE; UNITED STATES; UNSPECIFIED SIDE EFFECT; ATTITUDE TO HEALTH; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; INFORMATION PROCESSING; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PSYCHIATRY; STATISTICS;

ANTIPSYCHOTIC AGENTS; DATA COLLECTION; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; METABOLIC SYNDROME X; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRY; QUESTIONNAIRES; UNITED STATES;

EID: 77952935611     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Clark NG. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the study of obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-72.
3. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in clinical antipsychotic patients with schizophrenia; baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness [CATIE] schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
4. Moisan J, Grégoire JP, Gaudet M, Cooper D. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: A population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf 2005; 14: 427-36.
5. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine and risperidoneveterans health administration patients with Schizophrenia. Am J Epidemiol 2006; 164: 672-81.
6. Barrett E. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 2089-90.
7. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Res 2006; 83: 87-93.
8. Marlowe K, Howard D, Chung A. New onset Diabetes with Ketoacidosis attributed to Quetiapine. Southern Med J 2007; 100: 829-31.
9. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia Unxieta MT, Ramirez Bonilla ML, Gonzalez Blanch C, et al. A 12 week Randomized clinical trial to evaluate metabolic changes in Drug-Naïve, First-Episode Psychosis Patients treated with Haloperidol, Olanzapine or Risperidone. J Clin Psychiatry 2007; 68: 1733-40.
10. Yamuchi T, Tice A. Metabolic abnormalities associated with atypical antipsychotics: a case report and alert. Hawaii Med J 2007; 66: 12-3.
11. Newcomer J, Nasrallah H, Loebel A. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: Practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24: S1-6.
12. Ketter TA, Haupt DW. Perception of weight gain and bipolar pharmacotherapy; result of a 2005 survey of physicians in clinical practice. Curr Med Res Opin 2006; 22: 2345-53.
13. Cuffel B, Martin J, Joyce AT. Lipid and glucose monitoring during atypical antipsychotic treatment: effects of 2004 ADA/APA consensus statement [Poster]. Presented at 159th annual meeting of the American Psychiatric Association 2006 May 20-25; Toronto, Ontario, Canada.